Loading
Life sciences · Journal article
P a Herzen Journal of Oncology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective. To develop and validate a simplified method for rapid assessment of cardiovascular risk in oncology patients with breast cancer (BC), which does notrequire special equipment or the involvement of a cardiologist. Material and methods. The method is based on a systematic analysis of 93 publications (>50.000 patients) and uses the HR coefficient of 1.21 for every 1 Gy of average heart dose, which is based on the central estimate of the range of modern studies: the fundamental study by Darby et al. (2013) — HR=1.074/Gr; Chung et al. (2021) — HR=1.23/Gr; Van den Bogaard et al. (2021) — HR=1.269/Gr; average of the range: (1.165+1.269)÷2=1.217≈1.21. A software calculator has been created. A prospective single-center validation study was conducted at the Voronezh Regional Research and Clinical Oncology Center (n=125 patients, median follow-up of 24 months). Results. The calculator demonstrated excellent prognostic accuracy in the single- center study: AUC=0.89 (95%CI: 0.85—0.93), good calibration (Hosmer—Lemeshow test p = 0.137). Three-level risk stratification showed a cardiac event rate of 2.6% in the low-risk group, 14.7% in the moderate-risk group, and 78.6% in the high-risk group (p<0.001). The time spent by a physician to assess risks using the software calculator is 4.2 minutes. Conclusion. The developed software calculator demonstrated high efficacy in a single-center study. For its widespread implementation in Russian clinical practice, a multicenter study involving oncology institutions from various federal districts is necessary.